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Abstract
Background: We assessed the value of monocyte to high-density lipoprotein cholesterol ratio 
(MHR) in predicting in-hospital and 5-year mortality and major adverse cardiovascular events 
(MACE) in ST-segment elevation myocardial infarction (STEMI) patients.
Methods: A group of 1,598 patients were enrolled and divided into tertiles according to MHR val-
ues. The effects of different variables on clinical outcomes were assessed by Cox regression analysis.
Results: MHR was found as an independent predictor of in-hospital mortality (HR = 3.745, 
95% CI 1.308–5.950), in-hospital MACE (HR 1.501, 95% CI 1.015–1.993, p = 0.022) and 
5-year mortality (HR = 2.048, 95% CI 1.225–4.091, p = 0.014) and 5-year MACE (HR 
1.285, 95% CI 1.064–1.552, p = 0.009).
Conclusions: MHR is an independent predictor of in-hospital and long term mortality and 
MACE in STEMI. (Cardiol J 2016; 23, 5: 505–512)
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Introduction
It is well known that inflammation and oxida-
tive stress play a crucial role in the pathogenesis 
of all phases of atherosclerosis [1, 2]. Among the 
subtypes of leucocytes, monocytes are especially 
important in the pathogenesis of atherosclerosis 
due to their secretion capability of pro-inflamma-
tory and pro-oxidant cytokines [3]. In contrast, 
high density lipoprotein cholesterol (HDL-C) was 
shown to have anti-inflammatory, anti-oxidant, and 
anti-thrombotic effects [4, 5]. Association of high 
monocyte count and low HDL-C with inflammation 
and oxidative stress led physicians to testing a new 
marker called monocyte to high-density lipoprotein 
cholesterol ratio (MHR) in cardiovascular condi-
tions. First, Kanbay et al. [6] found that increased 
MHR is associated with major cardiovascular 
events in chronic kidney disease. Subsequent 
studies revealed the association of MHR with 
atrial fibrillation recurrence after cryoballoon-based 
catheter ablation, coronary slow flow, coronary ar-
tery ectasia and stent thrombosis after ST-segment 
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Recently, Karataş et al. [11] demonstrated that 
MHR values were independently associated with 
in-hospital mortality in patients with STEMI. How-
ever, value of the MHR in prediction of long-term 
prognosis of STEMI patients has not been studied 
so far. Therefore, the aim of the present study was to 
investigate the relationship of MHR with in-hospital 
and 5-year major adverse cardiac events (MACE) 
and mortality of STEMI patients managed with 
primary percutaneous coronary intervention (PCI).
Methods
Study population
One thousand, five hundred and ninety-eight 
consecutive patients with STEMI, who were admit-
ted to the Emergency Department and underwent 
urgent cardiac catheterization between December 
2009 and December 2013, were enrolled into the 
study. Patients with acute infection, hematological 
diseases, malignancy, and chronic systemic dis-
ease were excluded from the study. The patients 
were divided into tertiles according to their MHR 
levels. STEMI was defined as ischemia symptoms 
and ≥ 1 mm ST-segment elevation of in at least 
2 contiguous electrocardiogram (ECG) leads ex-
cept V2–V3 which required 1.5 mm for female 
patients, 2 mm for male patients > 40 years old, and 
2.5 mm for male patients < 40 years old or new 
onset left bundle-branch block. The study protocol 
was approved by the Institutional Ethics Committee.
Analysis of patient data
The demographic information, medical history, 
and cardiovascular risk factors of the patients were 
obtained from their medical records. On admission, 
blood values were obtained from all patients. A 12-
-lead ECG was recorded in each patient just after 
hospital admission, and the myocardial infarction 
type was also obtained from the ECGs. From 24 h 
to 72 h after revascularization, a transthoracic 
echocardiography was performed by using a system 
V (Vingmed, GE, Horten, Norway) with a 2.5-MHz 
phased-array transducer, and the left ventricular 
ejection fraction (LVEF) was calculated using 
a modified Simpson’s method.
Coronary angiography and PCI
All patients were given a chewable 300 mg 
aspirin and 600 mg loading dose of clopidogrel 
before coronary angiography. After the procedure, 
all patients were prescribed 100 mg aspirin and 
75 mg clopidogrel daily. Angiographic data of the 
patients were assessed from catheter laboratory 
records. All procedures were performed via femo-
ral route. Angiographic evaluation was made by 
visual assessment. Primary angioplasty (including 
balloon angioplasty and/or stent implantation) was 
performed just for infarct-related artery according 
to lesion type. For each procedure, interventional 
success at the acute phase was defined as reduc-
ing to < 30% of obstruction and stenosis of the 
infarct-related artery with Thrombolysis in Myo-
cardial Infarction (TIMI) 3 flow just after primary 
angioplasty. The use of tirofiban was left to the 
discretion of the operator.
Laboratory analysis
Basic hematologic parameters, such as mono-
cyte count were determined by a Coulter LH Series 
hematology analyzer (Beckman Coulter, Inc, Hia-
leah, Florida). Serum total cholesterol, triglyceride, 
and HDL-L concentrations were analyzed by a BM-
Hitachi-747 auto analyzer (Boehringer Mannheim 
GmbH, Mannheim, Germany). Serum low-density 
lipoprotein cholesterol (LDL-L) values were es-
timated by the formula of Friedewald or directly 
measured if triglyceride > 400 mg/dL.
Definitions
Patients were assessed according to Killip 
classification [14]. Non-diabetic patients were 
defined as patients without documented diabetes 
using neither oral hypoglycemic agents nor insulin 
treatment at admission. Hypertension was defined 
as systolic blood pressure ≥ 140 mm Hg or diastolic 
blood pressure ≥ 90 mm Hg or current antihyper-
tensive medicine use; a family history of coronary 
artery disease was defined as documented case of 
coronary artery disease in a parent or sibling before 
60 years of age; smoking was defined as current 
tobacco use; in-hospital mortality was defined as 
mortality due to any cause during hospital stay, and 
long-term mortality was defined as mortality due 
to any cause during 60 month follow up; in-hospital 
MACE was defined as reinfarction, stroke, target 
vessel revascularization, ventricular arrhythmia, 
cardiopulmonary resuscitation and death during 
index hospitalization; long term MACE was defined 
as death, stroke, reinfarction and target vessel 
revascularization during 60-month follow-up.
Statistical analysis
Analyses were performed using SPSS Statistics 
version18.0 for Windows (SPSS Inc, Chicago, IL). 
The Kolmogorov-Smirnov method was used to 
test the distribution pattern. Data were presented 
as mean and standard deviation, median and in-
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terquartile range, or proportions. The one way 
ANOVA was used to compare data with normal 
distribution and Kruskal-Wallis test was applied 
to compare the data without normal distribution. 
Categorical variables were compared with the c2 
test. The effects of different variables on clinical 
outcomes were assessed by Cox regression analy-
sis. The variables for which the unadjusted p value 
was < 0.10 in univariate Cox regression analysis 
were identified as potential risk markers and in-
cluded in the multivariable Cox regression model. 
Monocyte to HDL ratio was used as a continuous 
variable rather than tertiles in Cox regression 
models. The survival curves during hospitalization 
and follow-up for MHR were analyzed using the 
Kaplan-Meier method, and statistical assessment 
was performed using the log-rank test. A p value 
< 0.05 was considered statistically significant for 
all analyses.
Results
Baseline characteristics of the study popula-
tion are summarized in Table 1. Mean age of the 
participants was 56.1 ± 11.8 years and mean 
follow-up duration was 23.4 ± 15.8 months. Twenty- 
-three (1.4%) patients died during hospital stay and 
132 (8.7%) patients died during the follow-up. In 
multivariate Cox regression analysis, age (HR = 
= 1.144, 95% CI 1.067–1.227, p = 0.001), HDL 
(HR = 0.894, 95% CI 0.819–0.977, p = 0.013), 
white blood cell (WBC) count (HR = 1.258, 95% 
CI 1.010–1.459), and MHR (HR = 3.745, 95% CI 
1.308–5.950) were found as independent predic-
tors of in-hospital mortality (Table 2). Monocyte 
to HDL ratio was also found as an independent 
predictor of long-term mortality (HR = 2.048, 95% 
CI 1.225–4.091, p = 0.014) along with diabetes 
mellitus (HR = 2.279, 95% CI 1.197–4.340, p = 
= 0.012), LVEF (HR = 0.958, 95% CI 0.938–0.978, 
p < 0.001), and hemoglobin (HR = 0.795, 95% 
CI 0.679–0.930, p = 0.004) (Table 3), while WBC 
count (HR = 1.073, 95% CI 1.000–1.152, p = 0.049) 
and MHR (HR 1.501, 95% CI 1.015–1.993, p = 0.022) 
were found as independent predictors of in-hospital 
MACE (Table 4). In addition, LVEF (HR 0.980, 95% 
CI 0.967–0.993, p = 0.003), hemoglobin (HR 0.909, 
95% CI 0.829–0.996, p = 0.041), and MHR (HR 
1.285, 95% CI 1.064–1.552, p = 0.009) were found 
as independent predictors of long-term MACE 
(Table 5). Kaplan-Meier curves among tertiles 
for both in-hospital and 5-year MACE and mor-
tality, which represent worse outcomes as MHR 
increases, were shown in Figure 1.
Discussion
The main finding of the present study was 
that MHR level is independently associated with 
both in-hospital and 5-year MACE, and mortality of 
STEMI patients. As far as we know, this is the first 
study to report relationship of MHR with long-term 
prognosis in STEMI. In addition, findings of this 
study confirm a previous study with smaller patient 
count [11] revealing the association of in-hospital 
mortality and MACE with MHR in STEMI.
Monocytes are essential immune system cells 
with unique roles during inflammatory response 
and contribute the pathophysiology of all stages 
of atherosclerosis. In the presence of endothelial 
dysfunction, monocytes attach to endothelium 
and migrate to sub-endothelial space where they 
mature into macrophages which then differentiate 
into the foam cells by taking up oxidized LDL via 
scavenger receptors SR-A and CD-36 [12]. Next, 
foam cells secrete pro-inflammatory cytokines, 
matrix metalloproteinases, growth factors and 
tissue factor [13]. As a result, smooth muscle 
proliferation occurs and results in plaque growth. 
Furthermore, matrix metalloproteinases inflict 
damage to elastic lamina and predispose to plaque 
rupture. If the plaque rupture occurs, tissue fac-
tor acts as a co-factor for factor VII and causes 
thrombin production resulting in thrombus forma-
tion and acute coronary syndromes [14]. Impact 
of the monocytes on atherosclerosis seems to be 
correlated with circulating monocyte count which 
was found to be predictive of new plaque develop-
ment [15, 16].
As the so-called good cholesterol, HDL-C 
protects endothelial cells from inflammation and 
oxidative stress by several mechanisms. First, 
HDL-C prevents monocyte recruitment into the 
artery wall by inhibiting the expression of endothe-
lial adhesion molecules [17]. In addition, HDL-C 
has a role in control of the monocyte activation and 
proliferation of monocyte progenitor cells [18–20]. 
Furthermore, HDL-C inhibits oxidation of LDL-C 
and promotes efflux of oxidized LDL-C from foam 
cells [5, 18].
Association of HDL-C and inflammation is not 
just about the anti-inflammatory action of HDL-C. 
During inflammation, there is a reduction in levels 
of HDL-C and some plasma proteins are involved 
in HDL-mediated reverse cholesterol transport and 
inhibiting plasma lipid oxidation, such as apolipopro-
tein A-I and paraoxonase [21]. In addition, HDL-C 
loses cholesterol ester but gains free cholesterol, 
triglyceride, and free fatty acids [22]. The levels 
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Table 1. Clinical and laboratory characteristics of monocyte to high-density lipoprotein cholesterol ratio 
(MHR) tertiles.
Variables MHR P
Tertile 1 (n = 533) Tertile 2 (n = 533) Tertile 3 (n = 532)
Age [years] 58.2 ± 12.2 55.9 ± 11.4 54.4 ± 11.5 < 0.001
Gender (male) 423 (79.4%) 455 (85.4%) 463 (87.0%) 0.002
Diabetes mellitus 130 (24.5%) 110 (20.9%) 138 (26.1%) 0.125
Hypertension 210 (41.5%) 196 (38.4%) 200 (39.6%) 0.587
Family history of CAD 103 (21.1%) 94 (18.8%) 93 (28.9%) 0.573
Smoking 267 (54.9%) 325 (65.3%) 332 (67.5%) < 0.001
Ejection fraction [%] 48.9 ± 10.7 48.1 ± 11.4 46.9 ± 11.7 0.121
Glucose [mg/dL] 156.7 ± 68.8 148.5 ± 68.9 151.5 ± 67.5 0.143
Creatinine [mg/dL] 0.95 ± 0.45 0.97 ± 0.31 0.98 ± 0.34 0.348
Cholesterol [mg/dL] 189.7 ± 42.3 192.1 ± 43.5 184.4 ± 41.7 0.011
LDL [mg/dL] 118.9 ± 35.5 118.8 ±33.9 115.6 ± 35.8 0.257
HDL [mg/dL] 43.6 ± 10.2 40.7 ± 8.1 38.1 ± 8.2 < 0.001
Triglycerides [mg/dL] 141.2 ± 104.4 154.4 ± 109.1 151.4 ± 82.1 0.093
Hemoglobin [g/L] 13.4 ± 1.7 13.8 ± 1.6 13.9 ± 1.6 < 0.001
WBC [× 103/mL] 11.7 ± 3.4 12.0 ± 3.2 13.9 ± 3.9 < 0.001
Monocyte [× 103/mL] 0.374 ± 0.159 0.798 ± 0.195 1.018 ± 0.471 < 0.001
Platelets [× 103/mL] 256.0 ± 73.8 250.9 ± 62.5 272.5 ± 74.6 < 0.001
MHR 8.63 ± 3.10 19.8 ± 3.8 30.1 ± 10.5 < 0.001
Postprocedural TIMI grade:
1 45 (8.4%) 39 (73%) 50 (9.4%) 0.735
2 24 (4.5%) 27 (5.1%) 23 (4.3%)
3 464 (87.1%) 467 (87.6%) 459 (86.3%)
Peak CK-MB [U/L] 208 ± 145 215 ± 171 231 ± 184 0.073
Intervention:
Balloon angioplasty 16 (3.0%) 16 (3.0%) 16 (3.0%) 0.465
BMS 149 (28.0%) 147 (27.6%) 142 (26.7%)
DES 368 (69.0%) 370 (69.4%) 375 (70.3%)
Tirofiban use 145 (27.2%) 156 (29.3%) 158 (29.7%) 0.598
Pain to balloon time [h] 3.3 ± 2.3 3.1 ± 2.2 3.2 ± 2.5 0.636
In-hospital MACE 24 (4.5%) 44 (8.2%) 59 (11.1%) < 0.001
5-year MACE 114 (21.3%) 135 (25.3%) 169 (31.8%) 0.001
In-hospital mortality 5 (0.9%) 6 (1.1%) 17 (3.2%) 0.008
5-year mortality 27 (5.1%) 43 (8.1%) 62 (11.7%) < 0.001
BMS — bare metal stent; CAD — coronary artery disease; CK-MB — creatine kinase myocardial band; DES — drug eluting stent; HDL — high 
density lipoprotein; LDL — low density lipoprotein; MACE — major adverse cardiac events; TIMI — Thrombolysis in Myocardial Infarction; 
WBC — white blood cell
of apolipoprotein J and serum amyloid-A increase 
several fold in this “acute-phase HDL” [23]. Acute 
phase HDL behaves differently from normal HDL 
and was shown to be less effective in removing 
cholesterol from macrophages [24]. Thereforeo, 
HDL-C is a negative acute phase reactant and lower 
HDL-C levels may reflect more inflammation, as 
well as less anti-inflammatory activity.
Value of the MHR has been revealed in several 
cardiovascular conditions so far [6–11]. In addition, 
our study showed that MHR was found to be an inde-
pendent predictor of long-term prognosis of STEMI 
patients, while such an association was not present 
for monocyte or HDL-C alone. Thus, as a combina-
tion of two parameters related with inflammation 
and oxidative stress, MHR may have potential to be 
508 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 5
Table 2. Significant predictors of in-hospital mortality in univariable and multivariable Cox regression 
analyses.
Variables Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age 1.129 (1.031–1.236) 0.009 1.144 (1.067–1.227) 0.001
Male gender 1.483 (0.198–11.116) 0.701 – –
Diabetes mellitus 1.259 (0.254–6.211) 0.778 – –
Hypertension 0.568 (0.238–1.354) 0.202 – –
Smoking 0.209 (0.027–1.640) 0.136 – –
Glucose 1.002(0.996–1.009) 0.477 – –
Ejection fraction 0.969 (0.913–1.028) 0.291 – –
Cholesterol 1.015 (0.992–1.038) 0.203 – –
HDL 0.845 (0.752–0.949) 0.005 0.894 (0.819–0.977) 0.013
Triglyceride 0.991 (0.977–1.005) 0.191 – –
WBC 1.241 (1.007–1.529) 0.043 1.258 (1.010–1.459) 0.028
Monocyte 1.629 (0.956–2.777) 0.072 1.815 (0.902–2.964) 0.096
Hemoglobin 0.745 (0.448–1.239) 0.257 – –
Platelet 1.006 (0.999–1.014) 0.093 1.005 (0.998–1.011) 0.171
Peak CK-MB 1.003 (0.999–1.006) 0.142 – –
MHR 3.120 (3.058–3.184) 0.003 3.745 (1.308–5.950) 0.008
CI — confidence interval; CK-MB — creatine kinase myocardial band; HDL — how density lipoprotein cholesterol; HR — hazard ratio;  
MHR — monocyte to high density lipoprotein cholesterol ratio; WBC — white blood cell
Table 3. Significant predictors of mortality at 5-year follow-up in univariable and multivariable Cox  
regression analyses.
Variables Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age 1.018 (0.989–1.047) 0.220 – –
Male gender 1.426 (0.728–2.794) 0.300 – –
Diabetes Mellitus 2.012 (1.039–3.894) 0.038 2.279 (1.197–4.340) 0.012
Hypertension 1.215 (0.853–1.731) 0.281 – –
Smoking 0.959 (0.541–1.702) 0.887 – –
Glucose 1.003 (1.000–1.006) 0.091 1.003 (0.999–1.006) 0.116
Ejection fraction 0.959 (0.938–0.980) < 0.001 0.958 (0.938–0.978) < 0.001
Cholesterol 0.994 (0.968–1.002) 0.156 – –
HDL 1.023 (0.990–1.057) 0.167 – –
Triglyceride 1.001 (0.998–1.004) 0.600 – –
WBC 1.026 (0.949–1.109) 0.525 – –
Monocyte 1.584 (0.945–2.532) 0.164 – –
Hemoglobin 0.850 0.705–1.024) 0.087 0.795 (0.679–0.930) 0.004
Platelet 1.000 (0.996–1.004) 0.920 – –
Peak CK-MB 1.000 (0.998–1.001) 0.713 – –
MHR 2.472 (1.547–3.952) < 0.001 2.048 (1.225–4.091) 0.014 
CI — confidence interval; CK-MB — creatine kinase myocardial band; HDL — how density lipoprotein cholesterol; HR — hazard ratio;  
MHR — monocyte to high density lipoprotein cholesterol ratio; WBC — white blood cell
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Table 4. Significant predictors of in-hospital major adverse cardiac events in univariable and  
multivariable Cox regression analyses.
Variables Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age 0.985 (0.954–1.017) 0.349 – –
Male gender 0.897 (0.349–2.307) 0.822 – –
Diabetes mellitus 1.645 (0.747–3.624) 0.217 – –
Hypertension 0.720 (0.489–1.160) 0.108 – –
Smoking 1.070 (0.549–2.086) 0.842 – –
Glucose 0.998 (0.993–1.002) 0.289 – –
Ejection fraction 1.004 (0.977–1.032) 0.775 – –
Cholesterol 1.007 (0.998–1.016) 0.130 – –
HDL 0.961 (0.918–1.006) 0.092 0.976 (0.942–1.010) 0.162
Triglyceride 0.997 (0.993–1.001) 0.153 – –
WBC 1.092 (1.001–1.191) 0.046 1.073 (1.000–1.152) 0.049
Monocyte 1.584 (0.962–1.632) 0.073 1.488 (0.882–1.742) 0.102
Hemoglobin 0.921 (0.746–1.139) 0.449 – –
Platelet 1.001 (0.997–1.005) 0.611 – –
Peak CK-MB 0.999 (0.998–1.001) 0.456 – –
MHR 1.476 (1.116–1.944) 0.030 1.501 (1.015–1.993) 0.022
CI — confidence interval; CK-MB — creatine kinase myocardial band; HDL — how density lipoprotein cholesterol; HR — hazard ratio;  
MHR — monocyte to high density lipoprotein cholesterol ratio; WBC — white blood cell
Table 5. Significant predictors of major adverse cardiac events at 5-year follow-up in univariable and 
multivariable Cox regression analyses.
Variables Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Age 1.014 (0.997–1.030) 0.102 – –
Male gender 0.860 (0.558–1.326) 0.494 – –
Diabetes mellitus 1.138 (0.762–1.698) 0.528 – –
Hypertension 1.084 (0.883–1.330) 0.440 – –
Smoking 1.413 (1.09–1.979) 0.044 1.294 (0.945–1.773) 0.108
Glucose 1.003 (1.001–1.005) 0.010 1.004 (0.996–1.012) 0.080
Ejection fraction 0.981 (0.967–0.995) 0.007 0.980 (0.967–0.993) 0.003
Cholesterol 1.001 (0.997–1.006) 0.538 – –
HDL 1.000 (0.980–1.0120) 1.000 – –
Triglyceride 1.000 (0.998–1.002) 0.916 – –
WBC 1.020 (0.974–1.069) 0.400 – –
Monocyte 1.427 (0.973–1.988) 0.102 – –
Hemoglobin 0.916 (0.842–1.011) 0.082 0.909 (0.829–0.996) 0.041
Platelet 1.001 (0.999–1.003) 0.242 – –
Peak CK-MB 1.000 (0.999–1.001) 0.487 – –
MHR 1.248 (1.020–1.528) 0.031 1.285 (1.064–1.552) 0.009
CI — confidence interval; CK-MB — creatine kinase myocardial band; HDL — how density lipoprotein cholesterol; HR — hazard ratio;  
MHR — monocyte to high density lipoprotein cholesterol ratio; WBC — white blood cell
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Figure 1. Kaplan-Meier cumulative survival curves for in-hospital and 5-year mortality and major adverse cardiac 
events (MACE), according to monocyte to high density lipoprotein cholesterol tertiles; A. In-hospital MACE; B. In-
-hospital mortality; C. 5-year MACE; D. 5-year mortality.
a valuable prognosis marker in cardiology and deserve 
to be investigated in other cardiovascular conditions.
Limitations of the study
The present study has some limitations. First, 
it is a retrospective and single center study. In ad-
dition, a single MHR value was used for analysis 
rather than a temporal trend. Another limitation of 
the study is that other inflammation and oxidative 
stress markers, such as C-reactive protein, were 
not used. In addition, the use of newer drugs such 
as prasugrel and ticagrelor instead of clopidogrel 
may alter the results of the study.
Conclusions
In conclusion, results of the present study 
showed that MHR is an independent predictor 
of in-hospital and 5-year MACE and mortality in 
STEMI patients. Prospective studies are needed 
to confirm our findings and elucidate the value of 
MHR in prediction of prognosis after STEMI.
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